Updated Results of Rituximab Pre- and Post-BEAM with or without ⁹⁰Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

ABSTRACT: Purpose: We evaluated the effect on long-term survival of adding rituximab (R) to BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning with or without yttrium-90 ibritumomab tiuxetan (⁹⁰YIT) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous stem cell transplant (ASCT).Experimental design: Patients were enrolled on three consecutive phase II clinical trials. Patients received two doses of rituximab (375 and 1,000 mg/m²) during mobilization of stem cells, followed by 1,000 mg/m² on days +1 and +8 after ASCT with R-BEAM or ⁹⁰YIT-R-BEAM (⁹⁰YIT dose of 0.4 mCi/kg) conditioning.Results: One hundred thirteen patients were enrolled, with 73 receiving R-BEAM and 40 receivi

SUBMITTER: Chahoud J 

PROVIDER: S-EPMC5955837 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature